MOS — The Mosaic Company

Neutral-to-cautious, and the tape has stabilized rather than turned bullish. As of 2026-09-13 the stock sits at $25.20, mid-range between the 52-week low of $19.80 and high of $36.99, with a -14.1% six-month return but a +11.5% one-month return. Q2 2026 (reported 2026-08-04) delivered a $273M GAAP net loss but a narrow adjusted EPS beat ($0.13 vs $0.12 consensus) on revenue that missed badly ($2.82B vs ~$3.10B expected, -6.0% YoY). Analysts are split rather than hostile — 15 buys, 26 holds, 8 sells, consensus 'Hold' with a ~$27 average target and a wide $17-$32 institutional range. Management's own actions (cutting FY26 capex to $1.2B, tending $1.4B of 2027-2029 notes in August 2026, maintaining the $0.22 quarterly dividend payable 2026-09-24) are read as damage control rather than distress, which is why sentiment is neutral rather than outright bearish.

Revenue is range-bound, not growing: quarterly revenue has oscillated between ~$2.6B and ~$3.5B since 2023 (Q3 2023 $3.55B → Q2 2026 $2.82B), with YoY prints swinging from +22.8% (Q3 2025 vs Q3 2024) to -7.5% (Q4 2025) to +14.4% (Q1 2026) to -6.0% (Q2 2026). That is commodity price/volume noise, not a growth trend. The real story is profitability: full-year 2025 was actually strong (revenue $11.68B, operating income $1.16B, net income $1.22B, gross margin 16.5%), then gross margin collapsed to 7.9% in Q1 2026 and 7.6% in Q2 2026 — essentially halved in two quarters — pushing operating income to -$372.9M and -$35.5M and net income to -$257.6M and -$272.8M. This is a sharp, recent, input-cost-driven compression (sulfur), not a multi-year structural decay of the revenue base. But it is also not a one-quarter blip: TTM free cash flow is roughly -$947M (OCF $444M vs capex $1,391M across the last four quarters), long-term debt has risen from $3.33B (2025-06-30) to $4.77B (2026-06-30), and stockholders' equity has fallen from $12.78B to $11.46B. The earnings downtrend is real; whether it is a cycle trough or a structural reset is the entire investment question.

Split verdict — cheap on assets, expensive on earnings. As of 2026-09-13 the trailing P/E of 126.0x on $0.136 TTM EPS is meaningless, but the forward P/E is not: at $25.20 against next-FY consensus EPS of $0.496, MOS trades at ~50.8x forward earnings, roughly 3x its 5-year average P/E of 16.49x. On the asset side, price-to-book is 0.699 (BVPS ~$36.07 on $11.46B equity and ~318M shares) versus a 5-year average P/S of 0.84 against a current 0.674. EV/EBITDA of ~7.9x and a 3.47% dividend yield round it out. Read plainly: the market is pricing MOS on book value and asset replacement cost, not on earnings, because nobody believes the current earnings level. The stock is genuinely cheap versus its own history on book and sales, and genuinely expensive versus its own history on forward earnings.

The stock at $25.20 is not pricing in a growth recovery — it is pricing in survival plus a partial 2027 normalization. Note the gap: next-FY consensus EPS is only $0.496, well below the $3.86 of EPS MOS actually earned in FY2025. If the Street believed in a fast snapback, forward EPS would be $1.50+, not $0.50. So the setup is asymmetric in an uncomfortable way: the bull case (0.70x book, asset value, 2027 margin recovery as RBC argues) is already partly reflected in a stock that has bounced 27% off its $19.80 low, while the bear case (sulfur stays expensive, trough extends, further impairments hit book value) is not reflected in any earnings support, since 50x forward earnings gives you no valuation floor. Translation: you are not being paid for the wait unless you get a price closer to book or clear evidence the margin has inflected. Watch gross margin, not EPS headlines.

Constructive but not stretched, as of 2026-09-13. RSI(14) stood at 57.65 — neutral, neither overbought nor oversold — with price 4.28% above the 20-day SMA, 9.29% above the 50-day SMA, and only 2.61% above the 200-day SMA. The 200-day relationship is the key tell: the stock has just reclaimed its long-term average, which is a momentum improvement, but it is doing so from a deep hole (-14.06% over six months), and the last week was negative (-2.55%). This looks like a range-bound recovery trade inside a $19.80-$36.99 52-week range, not a clean uptrend. Entry-timing implication: there is no momentum urgency here and no oversold discount either — a buyer at $25.20 is buying the middle of the range after an 11% bounce. Better risk/reward historically comes from either a pullback toward the $21-22 area (closer to book) or a confirmed break above the 200-day on volume.

• Sulfur input costs are the single dominant swing factor: record sulfur pricing and tight global availability (partly linked to geopolitical friction around the Strait of Hormuz) have compressed phosphate conversion margins industry-wide, and Mosaic has responded by cutting phosphate production rates (Bartow running at reduced capacity).
• Elevated interest rates raise the cost of carrying heavy fertilizer inventories and of refinancing debt — Mosaic completed cash tender offers in August 2026 to repurchase up to $1.4B of notes due 2027-2029, while long-term debt still rose from $3.33B to $4.77B YoY.
• Grower affordability and credit conditions, especially in Brazil (Mosaic Fertilizantes), periodically soft-pedal application volumes even when underlying grain demand is intact.
• Global grain/crop economics (corn and soy prices, farm income) drive fertilizer affordability and are the ultimate demand variable for both phosphate and potash.
• Trade policy and export flows — Chinese agricultural purchasing commitments support baseline demand, while phosphate export quota policies and potash trade dynamics can shift global supply/demand balances quickly.

• Q3 2026 earnings, expected ~2026-11-03 after the close — the single most important data point; investors need evidence that sulfur cost pressure is abating and that phosphate realized margins are bottoming.
• Execution of the guided $300M-$500M working capital reversal in H2 2026, which is the proof point for a second-half free cash flow recovery after ~-$947M TTM FCF.
• The cuts to FY26 capex (down to $1.2B) flowing through into 2027 cash generation, plus the August 2026 debt tender reducing near-term maturities.
• Sulfur price normalization — if record sulfur pricing rolls over, phosphate margins could re-rate quickly given the operating leverage in the segment.
• 2027 contract pricing for phosphate and potash; RBC's Outperform thesis explicitly rests on 2027 margin recovery and lower capex.
• Dividend sustainability — the $0.22 quarterly dividend (payable 2026-09-24) being maintained rather than cut would be a confidence signal; a cut would be a material negative catalyst.

• Sulfur cost pressure proves structural rather than cyclical, meaning the current ~7.6-7.9% gross margin is closer to the new normal than a trough — this is the thesis-killer.
• Cash burn and balance sheet deterioration: TTM free cash flow of roughly -$947M (OCF $444M vs capex $1,391M), long-term debt up ~$1.44B YoY to $4.77B, equity down ~$1.32B to $11.46B, and a ~$280M annual dividend that is not covered by free cash flow.
• Forward earnings support is thin: next-FY consensus EPS of just $0.496 means ~50.8x forward P/E at $25.20, so if the trough extends there is little valuation floor below book value.
• Asset impairment risk — the 2026 GAAP results already carry large non-cash charges (Q2 2026 GAAP EPS of -$0.86 vs adjusted +$0.13), and further write-downs would directly erode the book value that is currently the main valuation support.
• Phosphate rock and potash price/volume risk combined with Brazilian grower affordability and credit tightness in the Fertilizantes segment.
• Structural capital intensity — $1.2B+ of annual capex against an $8.0B market cap means free cash flow is inherently thin even in decent years, limiting the upside of any recovery.

Not a buy right now, though not a short either. Mosaic is a legitimate asset-value story trading at 0.70x book with a non-distressed balance sheet (D/E 0.51, current ratio 1.34) and real optionality if record sulfur costs normalize — the classic cyclical-trough setup. But the deterioration is broad and measurable: revenue -6.0% YoY, gross margin halved from 17.3% to 7.6% in two quarters, ~$947M of TTM free cash burn, $1.44B more long-term debt than a year ago, and a Street forward EPS estimate of $0.50 that offers no earnings support at $25.20. You are paid 3.47% to wait for a margin inflection whose timing nobody can call. The disciplined move is to wait for gross margin to reclaim ~12-13% or for the price to come back near the $21-22 area (closer to book) before treating this as a value entry rather than a value trap.

Two methods averaged. (1) Mid-cycle EV/EBITDA: normalized EBITDA of ~$2.0B (FY2025 ran ~$2.1-2.2B on $1.16B operating income plus ~$1.0B D&A, with 2026 H1 depressed by sulfur) at 6.5x — the low end of the 5-8x fertilizer-producer range, justified by no growth, heavy capital intensity and commodity price risk — gives $13.0B enterprise value; less net debt of ~$4.9B ($4.77B long-term debt plus ~$0.4B current maturities less $294M cash) and divided by ~317.8M shares (derived from the $8.01B market cap at $25.20) yields ~$25.50. (2) Book-value cross-check: BVPS of ~$36.07 ($11.46B equity / 317.8M shares) at 0.75x — the midpoint of the stock's recent 0.6-0.9x trough-to-normal P/B range — yields ~$27.05. Averaging the two gives $26.30, which sits ~4% above the 2026-09-13 price of $25.20 and is derived independently of the analyst consensus target.